Compare WLDN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | FTRE |
|---|---|---|
| Founded | 1964 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2006 | 2023 |
| Metric | WLDN | FTRE |
|---|---|---|
| Price | $67.85 | $20.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $114.50 | $14.06 |
| AVG Volume (30 Days) | 257.7K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $273,352,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.05 | $3.09 |
| P/E Ratio | $127.55 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $64.67 | $5.27 |
| 52 Week High | $137.00 | $21.12 |
| Indicator | WLDN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 28.21 | 76.09 |
| Support Level | $64.67 | $9.10 |
| Resistance Level | $85.06 | N/A |
| Average True Range (ATR) | 2.73 | 0.85 |
| MACD | 0.08 | 0.21 |
| Stochastic Oscillator | 5.20 | 85.73 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.